Changes in seroprevalence to hepatitis A in Victoria, Australia: A comparison of three time points

Vaccine

Volumn 30, Issue 42, 2012, Pages 6020-6026

  Heywood, A E ^a   Newall, A T ^a   Gao, Z ^a   Wood, J G ^a   Breschkin, A ^b   Nicholson, S ^b   Gidding, H F ^a   Dwyer, D E ^c   Gilbert, G L ^c,d   MacIntyre, C R ^a,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Australia; Epidemiology; Hepatitis A; Seroprevalence

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; CLINICAL EXAMINATION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; FEMALE; HEPATITIS A; HUMAN; INFANT; MALE; MIGRATION; MONITORING; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SAMPLE; SCHOOL CHILD; SEROPREVALENCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HUMANS; INFANT; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; VICTORIA; YOUNG ADULT;

EID: 84865570235     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.058     Document Type: Article

References (46)

1. Jacobsen K.H., Koopman J.S. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004, 132(6):1005-1022.
2. Hall R. Notifiable diseases surveillance, 1917 to 1991. Commun Dis Intell 1993, 17(11):226-236.
3. Australian Government Department of Health and Ageing. National Notifiable Diseases Surveillance System (NNDSS); 2011. [Available from: ]. http://www9.health.gov.au/cda/source/cda-index.cfm.
4. National Health, Medical Research Council The Australian immunisation handbook 2008, Australian Government Department of Health and Ageing, Canberra. 9th ed.
5. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006;55(No. RR-7).
6. Amin J., Gilbert G.L., Escott R.G., Heath T.C., Burgess M.A., Hepatitis A. epidemiology in Australia: national seroprevalence and notifications. Med J Aust 2001, 174(7):338-341.
7. Jacobsen K.H., Wiersma S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28(41):6653-6657.
8. Gidding H. Australia's national serosurveillance program. NSW Public Health Bull 2003, 14(4-5):90-93.
9. Gilbert G.L., Escott R.G., Gidding H.F., Turnbull F.M., Heath T.C., McIntyre P.B., et al. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol Infect 2001, 127(2):297-303.
10. Australian Bureau of Statistics. 3201.0 - Population by Age and Sex, Australian States and Territories, June 2010; 2010. [Available from: ]. http://www.abs.gov.au/.
11. Woolson R.F., Clarke WR Statistical methods for analysis of biomedical data 2002, John Wiley and Sons, Inc, New York. 2nd ed.
12. Zoubir A.M., Iskander D.R. Bootstrap techniques for signal processing 2004, Cambridge University Press, Cambridge, United Kingdom.
13. Australian Government Department of Health and Ageing. National Notifiable Diseases Surveillance System (NNDSS) data; 2011. [Available from: ]. http://www9.health.gov.au/cda/source/cda-index.cfm.
14. Australian Bureau of Statistics. Estimated resident population, Selected countries of birth, age and sex-30 June 1996 to 2009. 34120 - Migration, Australia; 2010. [Available from: ]. http://www.abs.gov.au/.
15. Australian Bureau of Statistics. 3401.0 Overseas arrival and departure data, Australia. Time-series spreadsheets. Table 9: Short-term Movement, Resident Departures - Selected Destinations: Original. January 1991-December 2008; 2009. [Available from: ]. http://www.abs.gov.au/.
16. World Health Organization (WHO), Department of Communicable Disease Surveillance and Response. Hepatitis A; 2000. [Available from: ]. http://www.who.int/.
17. Mohler-Kuo M., Steffen R., Bopp M., Jacobs R.J., Mutsch M. Prevalence of hepatitis A virus risk factors in a very low endemic country, Switzerland. Vaccine 2007, 25(52):8718-8725.
18. Ericsson C.D. Travel medicine: key to improved adult vaccination against hepatitis A and B. J Travel Med 2001, 8(Suppl. 1):S1-S2.
19. Morris-Cunnington M.C., Edmunds W.J., Miller E., Brown D.W. A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales. Am J Epidemiol 2004, 159(8):786-794.
20. Barnett E.D., Holmes A.H., Geltman P., Phillips S.L., Harrison T.S. Immunity to hepatitis A in people born and raised in endemic areas. J Travel Med 2003, 10(1):11-14.
21. Mutsch M., Spicher V.M., Gut C., Steffen R., Mutsch M., Spicher V.M., et al. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 2006, 42(4):490-497.
22. Nielsen U.S., Larsen C.S., Howitz M., Petersen E. Hepatitis A among Danish travellers 1980-2007. J Infect 2009, 58(1):47-52.
23. Askling H.H., Rombo L., Andersson Y., Martin S., Ekdahl K. Hepatitis A risk in travelers. J Travel Med 2009, 16(4):233-238.
24. Ward K., McAnulty J. Hepatitis A: who in NSW is most at risk of infection?. NSW Public Health Bull 2008, 19(1-2):32-35.
25. Zwar N., Streeton C.L. Pretravel advice and hepatitis A immunization among Australian travelers. J Travel Med 2007, 14(1):31-36.
26. Heywood A.E., Watkins R.E., Iamsirithaworn S., Nilvarangkul K., Macintyre C.R. A cross-sectional study of pre-travel health-seeking practices among travelers departing Sydney and Bangkok airports. BMC Public Health 2012, 12(1):321.
27. Lopez-Velez R., Bayas J.M. Spanish travelers to high-risk areas in the Tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention. J Travel Med 2007, 14(5):297-305.
28. Wilder-Smith A., Khairullah N.S., Song J.H., Chen C.Y., Torresi J. Travel health knowledge, attitudes and practices among Australasian travelers. J Travel Med 2004, 11(1):9-15.
29. Dahlgren A.L., Deroo L., Steffen R. Prevention of travel-related infectious diseases: knowledge, practices and attitudes of Swedish travellers. Scand J Infect Dis 2006, 38(11):1074-1080.
30. Van Herck K., Van Damme P., Castelli F., Zuckerman J., Nothdurft H., Dahlgren A.L., et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 2004, 11(1):3-8.
31. van Genderen P., van Thiel P., Mulder P., Overbosch D. Trends in knowledge, attitudes, and practices of travel risk groups toward prevention of hepatitis A: results from the Dutch Schiphol airport survey 2002 to 2009. J Travel Med 2011, 19(1):35-43. Group obotDSAS.
32. Park C.H., Cho Y.K., Park J.H., Jun J.S., Park E.S., Seo J.H., et al. Changes in the age-specific prevalence of hepatitis A virus antibodies: a 10-year cohort study in Jinju, South Korea. Clin Infect Dis 2006, 42(8):1148-1150.
33. Armstrong G.L., Bell B.P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002, 109(5):839-845.
34. Verhoeff L., Boot H.J., Koopman M., Mellema L., Van der Klis F., Reimerink J., et al. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect 2011, 139(8):1172-1180.
35. Broman M., Jokinen S., Kuusi M., Lappalainen M., Roivainen M., Liitsola K., et al. Epidemiology of hepatitis A in Finland in 1990-2007. J Med Virol 2010, 82(6):934-941.
36. Beutels P, Luyten J, Lejeune O, Hens N, Bilcke J, de Schrijver K, et al. Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België. KCE reports vol. 98A [Evaluation of universal and targeted hepatitis A vaccination programs in Belgium]; 2008. [Available at: ]. http://old.kce.fgov.be/Download.aspx%3FID=1388.
37. McQuillan GM, Kruszon-Moran D, Denniston MM, Hirsch R. NCHS Data Brief No. 27: Viral Hepatitis. Hyattsville, MD: National Center for Health Statistics; 2010. [Available at: ]. http://www.cdc.gov/nchs/data/databriefs/db27.htm.
38. Kelly H., Riddell M.A., Gidding H.F., Nolan T., Gilbert G.L. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002, 20(25-26):3130-3136.
39. Hanna J.N., Hills S.L., Humphreys J.L. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 2004, 181(9):482-485.
40. Bell B.P., Kruszon-Moran D., Shapiro C.N., Lambert S.B., McQuillan G.M., Margolis H.S. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 2005, 23(50):5798-5806.
41. Van Herck K., Jacquet J.M., Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011, 83(11):1885-1891.
42. Burgess M.A., McIntyre P.B., Hellard M., Ruff T.A., Lefevre I., Bock H.L. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine 2010, 28(10):2222-2226.
43. Van Damme P., Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007, 5(2):79-84.
44. Van Damme P., Leroux-Roels G., Law B., Diaz-Mitoma F., Desombere I., Collard F., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001, 65(1):6-13.
45. Wasley A., Fiore A., Bell B.P. Hepatitis A in the era of vaccination. Epidemiol Rev 2006, 28:101-111.
46. Gay N.J. A model of long-term decline in the transmissibility of an infectious disease: implications for the incidence of hepatitis A. Int J Epidemiol 1996, 25(4):854-861.